Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression, but investors appear unimpressed. The study ...
When a business leader or a college president writes about a strategic plan, I understand the temptation to turn the page. After all, what happens internally in most institutions has little impact on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback